The International Journal of Neuropsychopharmacology and Acta Psychiatrica Scandinavica. Dr Pironti also worked as research associate at the department of Psychiatry, University of Cambridge and has led an R&D department of a global biotech company focused in devising and testing nutraceutical and micronutrient interventions for children with ADHD.
He also has extensive experience in neuropsychological assessment as he worked in a neuropsychology lab specialized in assessment of neuro-degenerative diseases, such as dementia and mild cognitive impairment. In his experimental work he also use neuroimaging (functional magnetic resonance imaging – fMRI, and magnetoencephalography – MEG) and when he was in Milan his research focused on understanding structural brain changes related to dyslexia in patients suffering from dementia. Then, in 2006, he started to work at the Behavioural and Clinical Neuroscience Institute (BCNI) identifying early neurophysiological biomarkers in patients suffering from Mild Cognitive Impairment (MCI). At the same time, He was working on a neuroimaging project aimed at identifying neural mechanisms of regret in economic decision making. He also spent 6 months at York Neuroimaging Center using Magnetoecephalography (MEG) to better understand brain mechanisms related to synesthesia.